Chengdu Olymvax Stock Hits Day Low of CNY 28.60 Amid Price Pressure

Chengdu Olymvax Biopharmaceuticals, Inc. experienced a significant decline today, with the stock dropping by 8.04% as it reached an intraday low of CNY 28.60. This performance stands in contrast to the China Shanghai Composite, which fell by 3.05% on the same day. Over the past week, Chengdu Olymvax has seen a more pronounced decline of 31.48%, while its monthly performance reflects a decrease of 17.25%. Despite the recent downturn, the company has shown resilience over the longer term, boasting a 67.36% increase over the past year and a year-to-date performance of 19.91%. The firm has reported a robust growth in net sales of 25.38% and has achieved positive results for the last two consecutive quarters. Key financial metrics indicate a return on capital employed (ROCE) of 6.86% and an impressive interest coverage ratio of 1,289.5. Chengdu Olymvax operates within the pharmaceuticals and biotechnology sector, holding a market capitalization of CNY 13,893 million. The stock's price-to-earnings ratio stands at 247.00, reflecting its valuation in the current market landscape.